Chronic, low-grade, hepatic inflammation is the hallmark of the progression of MASLD to metabolic dysfunction-associated steatohepatitis (MASH), previously termed nonalcoholic steatohepatitis (NASH), which may progress to hepatic fibrosis, a major prognostic determinant for hepatic and extra-hepatic adverse outcomes in patients with MASLD [8]
Adults with overweight or obesity newly prescribed liraglutide (Victoza/Saxenda, Novo Nordisk), subcutaneous semaglutide (Ozempic/Wegovy, Novo Nordisk) or tirzepatide (Mounjaro/Zepbound, Eli Lilly) from 2018 to 2023 were included
Additionally, Zumpano says, this gel can bind with the bile in your gut, which is composed of cholesterol, and remove it with the bodys waste, thus reducing the amount of cholesterol in your body
You can't remove the excess diluent without affecting the compound